A phase II randomized trial assessing the combination of gemcitabine and pemetrexed [Alimta] in the first line treatment of locally advanced or metastatic non-small cell lung cancer

Trial Profile

A phase II randomized trial assessing the combination of gemcitabine and pemetrexed [Alimta] in the first line treatment of locally advanced or metastatic non-small cell lung cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2010

At a glance

  • Drugs Gemcitabine (Primary) ; Pemetrexed (Primary) ; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ANGEL
  • Most Recent Events

    • 08 Apr 2010 Status changed from recruiting to discontinued.
    • 01 Apr 2010 Interim results published in Lung Cancer.
    • 13 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top